4. Intangible Assets, Goodwill and Other

12 Months Ended

Dec. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure

4. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):


	2020						2019
	Life Science		Clinical Diagnostics		Total		Life Science		Clinical Diagnostics		Total
Balances as of January 1:
Goodwill	$	250.1	$	349.2	$	599.3	$	234.5	$	320.5	$	555.0
Accumulated impairment losses and write-offs	(41.8)		(293.4)		(335.2)		(41.8)		(293.4)		(335.2)
Goodwill, net	208.3		55.8		264.1		192.7		27.1		219.8

Acquisitions (see Note 2)	29.8		—		29.8		15.6		28.7		44.3
Other adjustments (see Note 2)	(2.0)		—		(2.0)		—		—		—


Period increase, net	27.8		—		27.8		15.6		28.7		44.3

Balances as of December 31:
Goodwill	277.9		349.2		627.1		250.1		349.2		599.3
Accumulated impairment losses and write-offs	(41.8)		(293.4)		(335.2)		(41.8)		(293.4)		(335.2)
Goodwill, net	$	236.1	$	55.8	$	291.9	$	208.3	$	55.8	$	264.1

Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):


	December 31, 2020
	Weighted-Average Amortization Period (years)	Purchase Price		Accumulated Amortization		Net Carrying Amount
Customer relationships/lists	5.51	$	116.6	$	(87.2)	$	29.4
Know how	4.75	196.6		(175.4)		21.2
Developed product technology	14.00	218.1		(107.1)		111.0
Licenses	7.73	65.6		(37.4)		28.2
Tradenames	7.82	6.6		(4.2)		2.4
Covenants not to compete	3.87	4.5		(2.0)		2.5

Other	—	0.1		(0.1)		—
Total definite-lived intangible assets		608.1		(413.4)		194.7
In-process research and development		4.8		—		4.8
Total purchased intangible assets		$	612.9	$	(413.4)	$	199.5


	December 31, 2019
	Weighted-Average Amortization Period (years)	Purchase Price		Accumulated Amortization		Net Carrying Amount
Customer relationships/lists	6.36	$	107.2	$	(74.3)	$	32.9
Know how	5.71	188.5		(162.6)		25.9
Developed product technology	8.31	144.2		(93.9)		50.3
Licenses	8.74	76.0		(44.4)		31.6
Tradenames	8.50	6.4		(3.6)		2.8
Covenants not to compete	6.01	3.2		(1.4)		1.8

Other	—	0.1		(0.1)		—
Total definite-lived intangible assets		525.6		(380.3)		145.3
In-process research and development		0.2		—		0.2
Total purchased intangible assets		$	525.8	$	(380.3)	$	145.5

No impairment losses related to goodwill and purchased intangibles were recorded in 2020 and 2019.

Amortization expense related to purchased intangible assets for the years ended December 31, 2020, 2019 and 2018 was $27.5 million, $23.5 million and $28.3 million, respectively. Estimated future amortization expense (based on existing purchased intangible assets) for the years ending December 31, 2021, 2022, 2023, 2024, 2025 and thereafter is $28.3 million, $25.1 million, $23.8 million, $20.7 million, $18.7 million, and $78.1 million, respectively.